---
run_id: halo-evidence-vs-diagnosis-validation-v7-generic-advice-prompted-08
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: generic_advice_prompted
run_number: 8
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 805
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `generic_advice_prompted`, run 8 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 805, on the frozen condition packet.

## Output

I recommend that you advise the CEO to choose the **Targeted Evidence Pass**.

### Reasoning: The "Revenue Mirage"
You are currently facing a classic "false positive" in a B2B SaaS environment. The upbeat story in the board packet is built on lagging indicators (revenue and renewals) that have been artificially inflated by sales tactics, rather than leading indicators (usage and retention) that prove product-market fit.

Here is the breakdown of why the other options are dangerous:

1.  **The Danger of Scaling (Option 1):** Scaling now is a bet on a mirage. 72% of your expansion revenue is tied to temporary discounts. This is not "growth"; it is "borrowing" revenue from the future to make the present look better. More critically, the 31% front-line retention rate is a catastrophic signal. If you scale quota and implementation hires now, you are simply accelerating the rate at which you onboard users who will abandon the product in seven days. You will create a massive churn event in 6–12 months that will be far harder to explain to the board than a cautious budget now.
2.  **The Danger of Narrowing (Option 3):** While the "auditor explainability" issue in insurance is a critical insight, pivoting the entire company's strategy based on a few trial queues is premature. You don't yet know if the insurance segment is a representative "canary in the coal mine" for the rest of the market or if it is a unique outlier with requirements that would alienate your other mid-market customers.

**The Evidence Pass is the only path that treats the current "success" as a hypothesis rather than a fact.** It allows you to decouple the "Sales Bump" (discounts and early renewals) from the "Product Value" (actual reviewer utility). By pausing discounts and instrumenting behavior, you force the product to stand on its own merits before you commit a year of capital and headcount to it.

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** Your CEO and Board are currently experiencing a "win." They believe the team is finally "disciplined" and "clear on its market." Recommending a pause to "gather more evidence" will be perceived by Sales leadership and the CEO as a lack of confidence, a desire to "over-analyze," or a move that kills the current positive momentum. In a high-pressure B2B environment, "slowing down to be right" is often viewed as "being too slow to win." You are risking political capital by challenging a narrative that makes the CEO look good to the board.

### Observable Evidence That Would Change My Mind
I would shift my recommendation to **Scale Broadly (Option 1)** if you can provide evidence of **"The Bridge."**

Currently, you have a gap: *Champions* love it, but *Reviewers* hate it. If you can find evidence that the Champions are not just "running samples," but are actively redesigning the workflow for the Reviewers—and that the Reviewers' 31% retention is actually increasing week-over-week as the Champions' enablement takes hold—then the product is simply suffering from a "learning curve" rather than a "value deficit."

If the data shows that the 31% retention is a *starting point* that trends upward toward 60-70% as users hit a "lightbulb moment," then the product is viable, and the risk of scaling is significantly lowered. Without that trend line, you are scaling a leak.
